Pfizer Inc. (NYSE:PFE) Shares Acquired by Conscious Wealth Investments LLC

Conscious Wealth Investments LLC grew its stake in Pfizer Inc. (NYSE:PFE) by 0.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 101,870 shares of the biopharmaceutical company’s stock after buying an additional 437 shares during the quarter. Pfizer accounts for about 2.0% of Conscious Wealth Investments LLC’s portfolio, making the stock its 27th largest holding. Conscious Wealth Investments LLC’s holdings in Pfizer were worth $2,940,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of PFE. Marshall Wace LLP lifted its holdings in shares of Pfizer by 279.3% in the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock valued at $150,481,000 after buying an additional 8,378,173 shares during the period. Swedbank AB purchased a new position in shares of Pfizer in the 1st quarter valued at about $172,902,000. International Assets Investment Management LLC purchased a new position in shares of Pfizer in the 3rd quarter valued at about $146,481,000. Pzena Investment Management LLC increased its stake in shares of Pfizer by 181.6% in the 1st quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock valued at $212,855,000 after purchasing an additional 4,947,000 shares in the last quarter. Finally, Van ECK Associates Corp increased its stake in shares of Pfizer by 21.8% in the 1st quarter. Van ECK Associates Corp now owns 15,813,328 shares of the biopharmaceutical company’s stock valued at $438,820,000 after purchasing an additional 2,829,178 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several recent analyst reports. Wells Fargo & Company lifted their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Sanford C. Bernstein began coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Citigroup began coverage on Pfizer in a research note on Friday. They set a “neutral” rating and a $30.00 price objective for the company. Finally, Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Price Performance

Shares of PFE stock traded down $0.19 during trading hours on Friday, reaching $28.45. The company had a trading volume of 26,091,111 shares, compared to its average volume of 36,849,277. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The company has a market capitalization of $161.21 billion, a price-to-earnings ratio of -474.17, a PEG ratio of 1.01 and a beta of 0.67. The stock has a fifty day moving average of $29.08 and a 200-day moving average of $28.51. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the prior year, the firm posted $0.67 earnings per share. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. On average, equities analysts anticipate that Pfizer Inc. will post 2.67 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.91%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is presently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.